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Atrial natriuretic peptide (ANP), whoseamyloid is responsible of isolated atrial amyloidosis(IAA), is known to play an important
role in the pathophysiology of congestive heart failure (CHF). We provide here the microscopic examination of atrial biopsies
from 36 young (mean 40 years) CHF patients distinguished in idiopathic dilated cardiomyopathy (DC) aﬀected and hypertrophic
Cardiomyopathy (HC) aﬀected, endorsing the presumptive association of early CHF with IAA. We utilized a multiple method,
using Congo red (CR) staining, CR ﬂuorescence (CRF), and immunohistochemistry to assess the presence of IAA in CHF.
Immunostaining showed a moderate deposition of IAA in the atrium surrounding working myocardium with small intracellular
deposits. Our ﬁndings suggest a monitoring of young CHF cases for the development of IAA. Our study also demonstrated how
the concurrent use of immunohistochemistry, CR, and CRF may greatly enhance the detection of low-grade amyloid deposits.
1.Introduction
Congestive heart failure (CHF) is a leading cause of mor-
bidity and mortality in developed countries [1]. In CHF,
increased mechanical stress and the inﬂuence of circulating
andmyocardialneurohormonesandcytokinesresultinacol-
lectiveprocessknownasmyocardialremodeling [2].Thispro-
cess involves two primary responses at the cellular level: (1)
hypertrophy,dysfunction, and deathofcardiacmyocytesand
(2) increased deposition and alteration of the cardiac extra-
cellularmatrix(ECM),oftenassociatedwithamyloiddeposi-
tion. Amyloid inﬁltration leads to ECM disruption resulting
in diastolic dysfunction from progressive thickening and
stiﬀening of the myocardium [3]. Until recently, the study
of the cellular and molecular biology of heart failure focused
almost exclusively on myocyte dysfunction, but novel ﬁnd-
ings on the mechanisms for accelerated amyloid disease
progression and impaired prognosis associated with amyloid
cardiac involvement [4, 5] gave a boost for the selection of
pharmacological blockersof this detrimental phenomenon.
In this study, we focused on isolated atrial amyloidosis
(IAA), whose incidence reaches 90% in the ninth decade
[6, 7]. IAA is limited to the atrial myocardium and is char-
acterized by the deposition of ﬁbrillar material derived from
atrialnatriureticpeptide(ANP),ahormonesecretedbyatrial
cardiomyocytes [8]. ANP plays an established integral role
in circulatory hemodynamics, although no relationship has
been demonstrated to link IAA and measures of cardiac
performance, including ejection fraction. This suggests that
conditions increasing ANP production do not necessarily
promote atrial amyloidogenesis. Since the incidence of IAA
inelderlyhearts ishigh, ANPamyloidosis hasbeenuntil now
neglected and considered an unavoidable ageing symptom.
On the other hand, atrial ﬁbrosis, that increases in several
pathologic conditions and mainly in CHF, has been demon-
strated to create a substrate promoting atrial ﬁbrillation,
increasing conduction heterogeneity with multiple wavelets
andfocalsourcesbeingapossiblemechanisms forthegenesis
of IAA also at an early age. In any case, amyloid deposi-
tion induces permanent structural alterations of the atria,
disturbing myocyte contractility and conduction, and causes
cellular toxicity by free radical accumulation, lipid peroxida-
tion, and apoptosis [9]. Based on such correlations between
peculiar CHF conditions and IAA aetiology, we provide2 The Scientiﬁc World Journal
the microscopic examination of human atrial biopsies from
CHF patients aﬀected by idiopathic dilated cardiomyopathy
(DC) or hypertrophic cardiomyopathy (HC) and from peo-
ple undergoing surgery for valve replacement and not af-
fected by CHF (control).
Hypertrophic and dilated cardiomyopathies are impor-
tant pathologies that increase myocardial mass, albeit with
distinct patterns of remodelling reviewed in [10, 11]. Hyper-
trophic cardiomyopathy produces ventricular wall thicken-
ing without increases in ventricular volume, whereas both
wall thickness and chamber volumes increase in dilated car-
diomyopathy. Contractile parameters further discriminate
between these pathologies, with systolic function preserved
orimprovedinhypertrophicheartsbutdiminishedindilated
cardiomyopathy.
Comparingthetwogroupsofpatients(CHFandcontrol)
we endorsed the presumptive association of CHF caused by
diﬀerent pathologies and early IAA.
The aimofthisstudy wasthereforeto histopathologically
characterize ANPamyloid inﬁltrations inyoung humanatria
aﬀected by DC as well as HC and to establish a correlation
between early IAA and CHF, pointing out the role of moni-
toring ANP amyloid for the diagnosis of CHF.
2.Materialsand Methods
This study was approved by the local ethic committee, and
informed consent for participation was obtained from all
patients. The investigation is conformed with the principles
outlined in the Declaration of Helsinki.
2.1. Tissue Samples. We examined 36 explanted hearts ob-
tained during cardiac transplantation. All 36 patients
(Table 1) had severe CHF: 21 had idiopathic dilated car-
diomyopathy (DC) and 15 had hypertrophic cardiomyopa-
thy (HC) (Table 1). DC was diagnosed based on electrocar-
diographic and chest roentgenographic ﬁndings of ventric-
ular disfunction supported by echocardiographic or angio-
graphic conﬁrmation of global ventricular dilatation, and
HC was diagnosed based on speciﬁc echocardiographic
criteria [12]. We examined also 10 atrial biopsies from pa-
tients undergoing surgery for valve transplantation and not
aﬀected by CHF (control group). In addition, to fulﬁll diag-
nosticcriteria,peopleolderthan45yearswereexcludedfrom
the study. Following cardiectomy, specimens were resected,
ﬁxed,andsubjectedtohistologicpreparation.Tissue samples
were ﬁxed in 10% phosphate-buﬀered formalin, embedded
in paraﬃn, and sectioned at 4μm thickness, and standard
histology with hematoxylin and Congo red (CR) staining
was performed. We adopted a multiple quantitative method,
using CR birefringence (CRB), CR ﬂuorescence (CRF), and
immunohistochemistry (IHC) to assess the morphometric
pattern of IAA in CHF.
2.2. Amyloid Diagnosis. CR-stained sections were evaluated
using Zeiss Axio Lab.A1 microscope with built-in polariza-
tion equipment, under polarized light to assess the presence
of green birefringence polarization. Amyloid was diagnosed
using CR staining method [13]. CR-stained paraﬃns e c t i o n s
were weakly counterstained with Mayer’s acid hemalum.
The characteristic green birefringence, when sited within the
tissue structure, was takenas a proof of the amyloid presence
[14–16].
2.3. Immunohistochemistry. Amyloid ANP was identiﬁed us-
ing the peroxidase-antiperoxidase (PAP) method using a
1/100 dilution of antisera against ANP peptide (Santa Cruz
Biotechnology, Inc, CA, USA). Moreover, to classify the type
of amyloid deposited in the heart, we performed immuno-
histochemical staining of tissues with appropriate commer-
cially available antisera (Santa Cruz Biotechnology, Inc, CA,
USA): antitransthyretin (TTR), antiamyloid A protein, and
immunoglobulin light chains antibodies were also tested.
2.4. CR Fluorescence. When CRB was negative, additional
paraﬃn sections were stained with CR and/or IHC for ANP
in cases where amyloid deposition was clinically and/or
pathologically suspected. CRF was evaluated under UV light
(ﬂuorescence microscope), and ﬂuorescence was induced on
CR-stained paraﬃn sections using a LED light as part of
a Zeiss Axio Lab.A1 microscope with photographic equip-
ment [14]. Filter set for detecting ﬂuorescein isothiocyanate
(FITC-blue) was used.
In case that CRF was positive, serial paraﬃns e c t i o n s
were stained with both CR and IHC for ANP, TTR, amyloid
A protein, and immunoglobulin light chains. CR-stained
sections were observed also by one of the investigators who
was blinded to the original results.
2.5. Statistical Analysis. All values were expressed as mean ±
SD. Continuous variables were compared by means of the
unpaired Student’s t-test. The χ2 test with Yates correction
and multivariance analysis method were used, where appro-
priate, to assess the association between the occurrence of
DC, HC, and IAA. The Pearson correlation coeﬃcient was
used to determine the relationship between metric parame-
ters. A value of P<0.05 was considered to be statistically
signiﬁcant.
3.Results
3.1. Assessment of ANP Amyloidosis in CHF Heart Specimens.
The presence and expression of atrial ANP in patients with
CHF were investigated in myocardial biopsies from patients
with DC(n = 21) and HC (n = 15), the average age being 40
and 41 years, respectively. In parallel, the presence of ANP
amyloidosis was tested in a control group of patients not
aﬀected by CHF (average age 42 years).
T h em e a nA N Pl e v e li na l lC H Fp a t i e n t sw a s8 8p g / m L±
10pgl/mL versus 42pg/mL ± 5pg/mL in the control group
(two tailed t-test, P<0.05). On multivariate analysis, higher
ANP levels were found to be associated signiﬁcantly with
CHF.
Both DC and HC hearts demonstrated prominent histo-
logicabnormalities, includingmyocytehypertrophy,myoﬁb-
rillar disarray, and ﬁbrosis (Figure 1). None of DC or HCThe Scientiﬁc World Journal 3
Table 1: Patients’ characteristics: values are means ± SD or n (%).
Characteristic Patients Amyloid not present Amyloid present P IAA DC HC P
Total control 10 10 0 0 0 0
Age, years, control 42.2 ±2.24 2 .2 ±2.20 0 0 0
Sex (M/F), control 4/6 4/6 0 0 0 0
Diabetes mellitus 2 10 0 0 0 0
Hypertension 6 10 0 0 0 0
ANP level 42pg/mL ± 9
Total CHF 36 3 33 31 21 15
Age, years, CHF 40.4 ±4.3
Sex (M/F) 20/16 3/0 17/16 15/16 13/8 7/8
Diabetes mellitus 11 (31) 2 (18.2) 9 (81.8) P<0.05 1 (9) 8 (72.7) 3 (27.2) P<0.05
Hypertension 26 (73) 1 (3.8) 25 (96.2) 25 (100) 21 (84) 4 (16)
ANP level 88pg/mL ± 10 3 33 P<0.05 21 15 P<0.05
IAA 31 3 28 P<0.05 31 20 11 P<0.05
DC 21 1 20 P<0.05 20 21 0 P<0.05
HC 15 2 13 P<0.05 11 0 15 P<0.05
hearts showed dystrophic calciﬁcation but multifocal inter-
stitial ﬁbrosis with slight perivascular ﬁbrosis was evidenced
in HC hearts (Figure 1).
An extensivestudyofatrial tissues from youngcardiomy-
opathic hearts showed that atria from dilated (DC) and
hypertrophic cardiomyopathy (HC) had an evident ANP
amyloid cardiac involvement.
In HC specimens, aﬀected myoﬁbers showed about a
threefold increase in their transverse diameters and nuclear
enlargement. Cells presented bizarre shapes, and the con-
nections among cells were often in disarray (Figure 1(c)).
Myocardial scarring and expansion of the collagen matrix
also occurred. Scarring and disarray may constitute the sub-
strate for arrhythmias. Other features observed were degen-
eration and inﬂammation (Figure 1(c)). Myoﬁber degener-
ation was present in the form of waviness, smudging, and
vacuolation (Figure 1(g)).
In DC biopsies myocyte injury was manifested as necro-
sis with anucleate, hypereosinophilic myocytes with both
nuclear loss and pyknosis (Figures 1(a)–1(e)). Inﬂammation
was focal, sparse, and interstitial (Figures 1(a)–1(e)).
ANPexpression was diﬀuselyobservedinHC(n = 11)as
well as in DC (n = 20) patients. No amyloid deposition was
observedatallinotherheart districts.2(5.,5%)casesshowed
additional TTR-positive amyloid deposits. No other anti-
body stained amyloid. On the contrary, none of the control
group specimens was positive for any kind of amyloidosis.
Patients with CHF were signiﬁcantly more likely to suﬀer
from IAA (P<0.05; Table 1) than those without CHF.
Table 1 summarizes the clinical characteristics of the
patients and the results of statistical analysis.
3.1.1. Assessment of ANP Amyloidosis in HC Heart Specimens.
In HC, ordered myoﬁbrillar arrangement was lost in ECM
invaded by amyloid deposits (Figures 1(g) and 2). Amyloid
inﬁltration was found in the perivascular areas (Figures
2(g)–2(j)) and amyloid in HC manifested as hypertrophied,
disorganized cardiac myocytes (Figures 1(c) and 1(g) and
Figure 2(j)).Strikingmyoﬁberhypertrophy waspresentinall
15 cases. Injury was commonly interstitial, interﬁbrillar and
in some cases perivascular. Biopsies obtained with overlying
adipose tissue at the site of sampling revealed an increased
penetranceoftheamyloidinﬁltration(Figures2(a)–2(d)).11
amyloid deposits were immunoreactive for ANP (Figure 2)
and 2 were positive for TTR. 2 HC patients were found to be
not aﬀected by amyloidosis.
Vessel involvement was found in 12 (80%) of HC sam-
ples, compared to only 2 (9.5%) of DC patients, the diﬀer-
ence being statistically signiﬁcant (P<0.01).
Since patients with HC had lower amounts of amyloid
in their hearts than patients with DC, in several cases CRF
supported CRB to detect amyloid (Table 2).
3.1.2. Assessment of ANP Amyloidosis in DC Heart Specimens.
ANP expression (Figure 3) was increased in cardiomyocytes
and also distributed diﬀusely throughout the atrium of
20DC patients. Importantly, left atrium from patients with
DC showed the presence of cardiomyopathic changes, con-
sisting of vacuolar degeneration of myocardial ﬁbers, often
showing amyloid inﬁltrations indicating the involvement of
amyloidosis in the cardiomyopathic process (Figures 1(a)–
1(e) and Figure 3).
Microscopically, injury was present in all cases as amor-
phous amyloid deposition gathered around myocytes of
the atrium wall (Figure 3). Transmural amyloid deposition
reaching through the whole atrial layer to the internal
border was visible in all 20 patients positive for amyloidosis,
but small vessel disease and inﬂammatory cell inﬁltration
were observed only in 2 cases. The maximum injury was
transmural in all lesions (Figure 3) with endothelial necrosis.
Notably,IAAwas found more commonly in women (P<
0.05).
Finally, patients with DC had larger amounts of amy-
loid in their heart specimens than patients with HC; CRF
was essentially used to conﬁrm the CRB-based diagnosis
(Table 2).4 The Scientiﬁc World Journal
(a) (b) (c)
(d) (e) (f)
(g) (h)
Figure 1: Histology of CHF hearts and CR birefringence: (a) and (b) epicardium of a DC patient with macrophage inﬁltrates; nonspeciﬁc
abnormalities, including variations in myocyte size, myocyte vacuolation, loss of myoﬁbrillar material, and ﬁbrosis (arrows), can be seen.
In (b) amyloid inﬁltration is visible as CRB. (c) Oblique and perpendicular arrangement of hypertrophied muscleﬁbres constituting HC
disarray. (d) CRB showing extensive amyloid deposition. (e) Particular of a vessel in the Purkinje of a DC patient with evident amyloid
deposition. (f) CRB. (g) Disarray characterised by oblique and perpendicular arrangement of myoﬁbril bundles in HC heart. Wide spaces
among ﬁbres are present (arrows). In (a), (c), (e) and (g) amyloid inﬁltration by CRB is shown. CR stain—original magniﬁcation: (a) 63x,
(c)–(e) 20x, and (g) 40x.
4.Discussion
In the extensive state-of-the-art papers on CHF and left atri-
um functional remodelling [17–19], IAA was never men-
tioned. Recently, longs tanding AF has been associated with
intra-atrial ANP amyloid [20], suggesting that AF-related
ANP overproduction leads to localized amyloidogenesis,
which in turn augments conduction heterogeneity, helping
to perpetuate AF (and thereby stimulating further ANP
productionin a paracrine loop)[20]. Inthisview, atrial ANP
amyloid could be considered a further negative consequence
of neurohormonal disturbances. Diﬀerent from what was
assumed in several physiological and clinical studies, ANP
plasma levels should not be considered a reliable estimation
of the amount of hormone produced by the heart and even
less of the overall ANP system activity because (i) plasma
ANP is 1/15 to 1/20 of the total body pool [21], and
(ii) plasma ANP half-life is very short (few minutes) [22].
Indeed, ANP plasma levels closely parallel the instantaneous
secretion rate, and therefore likely they greatly vary in
response to diﬀerent pathophysiological stimuli. The dis-
covery that ANP amyloid associated with atrial myoﬁbrils
in most human hearts with dilated or hypertrophic car-
diomyopathies [23, 24] suggests IAA as a potential major
pathogenic process in CHF. In the light of this, we recently
demonstrated the correlation between CHF and ANP amy-
loidosis [25]. In the present study we presented a detailed
description of deposition pattern of amyloid ANP in two
groups of young CHF patients, aﬀected respectively by DC
and HC, in order to deﬁnitively establish a correlation be-
tween CHF injuries and early ANP amyloidosis. Amyloid
deposits were found in 91,6% of CHF cases, 93,9% of whichThe Scientiﬁc World Journal 5
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
Figure 2: CR and anti-ANP immunostainingof HC heart specimens revealed the cooccurrence of CHF and IAA. CR-IHC-stained paraﬃn
sections from atria of representative HC patients showing atrial amyloid under direct light ((a), (d), (g), and (j)) and polarized light ((b),
(e), (h), (k)). ((c), (f), (i), (l)) CRF of ANP in the atrial myocardium. (a): Microscopic examination of a HC epicardium shows amorphous
deposits that were predominantly observable in the extracellular space and interstitium (arrows) expanded by an acellular eosinophilic
substance. (d)–(j) Extensive accumulation of amyloid was present between myocardial ﬁbers and in the vessel wall of a HC patient. (a) and
(d) also showed epicardial fat tissue (arrowheads). Original magniﬁcation:((a), (d), and (g)) 20x.
were also positive for ANP. At a cellular and molecular level,
the focus of therapy for CHF must increasingly include the
adverse changes in the ECM and cardiac amyloidosis [3].
During the past decades, medical management of heart fail-
ure has involved the blockade of the neurohormonal eﬀects
of angiotensin II, catecholamines, and aldosterone [23], but
a poly pharmaceutical approach to the treatment of heart
failure is emerging. However, as more antiamyloid therapies
emerge, the uniform treatment of patients with multiple
classes of medications is impractical and costly, so encour-
aging the prevention practices. The prevention of atrial ANP
amyloidosis likely reduces morbidity and mortality in heart6 The Scientiﬁc World Journal
(a) (b) (c)
ENDO
MYO
(d) (e) (f)
Figure 3: CR and anti-ANP immunostaining of DC heart specimens: CR-IHC-stained paraﬃn sections from atria of representative DC
patients showing atrial amyloid under direct light ((a) and (d)) and polarized light ((b) and (e)). ((c) and (f)) CRF of ANP in the atrial
myocardium. (a) Epicardium of a DC patient showing interstitial ﬁbrosis (arrows), loss of nuclei, and myoﬁber disarray. The image also
shows myoﬁbrillar disarray and disruption of sarcomeric architecture. (d) Transmural amyloid deposition reaching through the whole
myocardial layer to the endocardial border of a DC patient. Original magniﬁcation:(a) 20x, (d) 10x, and (g) 20x.
Table 2: Comparison between CRB, CRF, and IH methods in detecting amyloid: values are means ± SD or n (%).
Features Patients CRB negative CRB positive CRF negative CRF positive
Total control 10 10 (100) 0 (0) 10 (100) 0 (0)
Age, years, control 42.2 ±2.24 2 .2 ±2.204 2 .2 ±2.20
Diabetes mellitus
Hypertension
Total 36 10 (27.8) 26 (72.2) 3 (8.3) 33 (91.7)
Age, years 40.4 ±4.33 8 .5 ±1.54 2 .2 ±8.72 7 ±2.14 0 .8 ±3.9
Sex (M/F) 20/16 4/6 16/10 2/1 18/15
Disease
Hypertrophic cardiomyopathy 15 (41.7) 7 (46.7) 8 (53.3) 2 (13.3) 13 (86.7)
Idiopathic dilated cardiomyopathy 21 (58.3) 3 (14.3) 18 (85.7) 1 (4.8) 20 (95.2)
Immunohistochemistry
ANP negative 5 (13.9) 3 (60) 2 (40) 1 (20) 4 (80)
ANP positive 31 (86.1) 7 (22.6) 22 (77.4) 0 (0) 31 (100)
failure. The detection of speciﬁc biomarkers as natriuretic
peptideplasma levelsmay eventuallybecomeanintegral part
of CHF management in the individual patient.
Atrial amyloidosis, that we have shown to be increased in
CHF [25], has been demonstrated to create a substrate that
promotes AF and hypertrophy with degenerative changes
of myocytes is the most prominent histologic ﬁnding in all
examinedCHFpatients.Inparticular, myocytolysisandANP
interstitialamyloidosisseemedtobemorepronouncedinthe
left atrial, conﬁrming this location as an elective target for
the deposition of amyloid ANP. Moreover, the inﬂammatory
stage of the disease can involve also the entire atrial myo-
cardium and the release of cationic proteins by the activated
eosinophils may be responsible for the toxic damage of the
myocardial tissue. Based on these ﬁndings, we can infer that
processing of ANP precursor in the human failing heart
diﬀers from that in the normal heart, so if the protein home-
ostasis is altered under stress, age, or early CHF conditions,
hormone aggregation may be out of control and disease-
associated amyloid aggregation of hormone may occur.
Overall, ourﬁndings indicate that early IAA-relatedANP
deposition may occur in CHF and suggest that these latterThe Scientiﬁc World Journal 7
patients should be monitored for the developmentof cardiac
amyloidosis.
Our study also demonstrated how the concurrent use of
immunohistochemistry, CRB, and CRF was superior to the
CRB alone in cases in which amyloid deposits were low.
In fact, unfortunately, small amyloid deposits can be
missed at light microscopy using CRB [26, 27] alone. CRF is
recommended in all CRB-negative suspicious tissue samples
[14]. In our work, CR staining and IHC applied together
(CR-IHC) has been shown to be more sensitive than CR
alone. However, a recent report suggested that CRF is the
most sensitive method for the direct detection of amyloid
[14]. This combined procedure increased the recognition of
tissue-bound CR by virtue of its property as a ﬂuorochrome
[28], allowing an easier evaluation than CR in bright light.
CR, when combined with IHC, was still visible under UV
whereas CR was masked in bright light. Although not widely
used,theCRFmethodfordetectingamyloid issimple,highly
speciﬁc, and sensitive; therefore, we applied the CRF tech-
nique retrospectively to paraﬃn sections of heart biopsies
with the aim to evaluate the reported improved sensitivity
compared toCR staining and toassess whether it is a suitable
method if combined with IHC analysis for paraﬃnh e a r t
sections in order to detect also minor amyloid deposits.
In addition, unlike some previous reports where the sen-
sitivityofCRFwasreportedtobelowduetoartifacts[29],we
found complete concordance between the staining patterns
ofCRinbrightand UVlight.Thehighsensitivity ofCRFand
the speciﬁcity safe-guarded by green birefringence provide
a new tool for monitoring patients at risk for amyloidosis,
that is, young CHF patients as in this case. Earlier diagnosis
and chemical origin identiﬁcation of the amyloid will allow
earlier intervention, before the development of severe organ
damage [30].
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